262 related articles for article (PubMed ID: 23928147)
1. Preparation, characterization, biodistribution and antitumor efficacy of hydroxycamptothecin nanosuspensions.
Han M; Liu X; Guo Y; Wang Y; Wang X
Int J Pharm; 2013 Oct; 455(1-2):85-92. PubMed ID: 23928147
[TBL] [Abstract][Full Text] [Related]
2. 10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG
Yang L; Hong J; Di J; Guo Y; Han M; Liu M; Wang X
Int J Nanomedicine; 2017; 12():3681-3695. PubMed ID: 28553107
[TBL] [Abstract][Full Text] [Related]
3. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.
Pu X; Sun J; Wang Y; Wang Y; Liu X; Zhang P; Tang X; Pan W; Han J; He Z
Int J Pharm; 2009 Sep; 379(1):167-73. PubMed ID: 19505545
[TBL] [Abstract][Full Text] [Related]
4. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
5. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles.
Yang L; Cui F; Cun D; Tao A; Shi K; Lin W
Int J Pharm; 2007 Aug; 340(1-2):163-72. PubMed ID: 17482779
[TBL] [Abstract][Full Text] [Related]
6. [Pharmaceutical evaluation of hydroxycamptothecin nanosuspensions with the action of inhibiting P-gp].
Pu XH; Sun J; Qin YM; Zhang X; Zhang P; He ZG
Yao Xue Xue Bao; 2011 Jul; 46(7):834-8. PubMed ID: 22010354
[TBL] [Abstract][Full Text] [Related]
7. A nanoparticulate drug-delivery system for glaucocalyxin A: formulation, characterization, increased in vitro, and vivo antitumor activity.
Han M; Li Z; Guo Y; Zhang J; Wang X
Drug Deliv; 2016 Sep; 23(7):2457-2463. PubMed ID: 25715810
[TBL] [Abstract][Full Text] [Related]
8. A stabilizer-free and organic solvent-free method to prepare 10-hydroxycamptothecin nanocrystals: in vitro and in vivo evaluation.
Yang X; Liu Y; Zhao Y; Han M; Guo Y; Kuang H; Wang X
Int J Nanomedicine; 2016; 11():2979-94. PubMed ID: 27382284
[TBL] [Abstract][Full Text] [Related]
9. Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions.
Zhao YX; Hua HY; Chang M; Liu WJ; Zhao Y; Liu HM
Int J Pharm; 2010 Jun; 392(1-2):64-71. PubMed ID: 20302926
[TBL] [Abstract][Full Text] [Related]
10. High Drug Payload 10-Hydroxycamptothecin Nanosuspensions Stabilized by Cholesterol-PEG: In Vitro and In Vivo Investigation.
Yang L; Jiang J; Hong J; Di J; Liao Y; Kuang H; Wang X
J Biomed Nanotechnol; 2015 Apr; 11(4):711-21. PubMed ID: 26310077
[TBL] [Abstract][Full Text] [Related]
11. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice.
Zhang L; Yang M; Wang Q; Li Y; Guo R; Jiang X; Yang C; Liu B
J Control Release; 2007 Jun; 119(2):153-62. PubMed ID: 17400320
[TBL] [Abstract][Full Text] [Related]
12. Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect.
Wang A; Li S
BMC Biotechnol; 2008 May; 8():46. PubMed ID: 18454874
[TBL] [Abstract][Full Text] [Related]
13. Enhanced tumor targeting and antitumor efficacy via hydroxycamptothecin-encapsulated folate-modified N-succinyl-N'-octyl chitosan micelles.
Zhu H; Cao J; Cui S; Qian Z; Gu Y
J Pharm Sci; 2013 Apr; 102(4):1318-32. PubMed ID: 23400693
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application.
Wei W; Shi SJ; Liu J; Sun X; Ren K; Zhao D; Zhang XN; Zhang ZR; Gong T
J Drug Target; 2010 Aug; 18(7):557-66. PubMed ID: 20131981
[TBL] [Abstract][Full Text] [Related]
15. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying.
Zhang X; Pan W; Gan L; Zhu C; Gan Y; Nie S
Chem Pharm Bull (Tokyo); 2008 Dec; 56(12):1645-50. PubMed ID: 19043233
[TBL] [Abstract][Full Text] [Related]
16. Hydroxycamptothecin nanoparticles based on poly/oligo (ethylene glycol): Architecture effects of nanocarriers on antitumor efficacy.
Guo Y; Wang T; Qiu H; Han M; Dong Z; Wang X; Wang Y
Eur J Pharm Biopharm; 2019 Jan; 134():178-184. PubMed ID: 30529294
[TBL] [Abstract][Full Text] [Related]
17. Preparation and
Zhou T; Tang X; Zhang W; Feng J; Wu W
Drug Deliv; 2019 Dec; 26(1):673-679. PubMed ID: 31266376
[TBL] [Abstract][Full Text] [Related]
18. Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance.
Liu M; Chen D; Wang C; Chen X; Wen Z; Cao Y; He H
J Drug Target; 2015; 23(9):800-5. PubMed ID: 25766079
[TBL] [Abstract][Full Text] [Related]
19. Honokiol nanosuspensions: preparation, increased oral bioavailability and dramatically enhanced biodistribution in the cardio-cerebro-vascular system.
Han M; Yu X; Guo Y; Wang Y; Kuang H; Wang X
Colloids Surf B Biointerfaces; 2014 Apr; 116():114-20. PubMed ID: 24448177
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells.
Li Q; Liu C; Zhao X; Zu Y; Wang Y; Zhang B; Zhao D; Zhao Q; Su L; Gao Y; Sun B
Int J Nanomedicine; 2011; 6():397-405. PubMed ID: 21499429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
